SLS · Nasdaq · CIK 0001390478

SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. Its EDGAR record lists 12 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$26.9M
Form 4 filings on record, past 12 months
12

Company overview

Legal name (as filed)
SELLAS Life Sciences Group, Inc.
Ticker
SLS
SEC Central Index Key (CIK)
0001390478
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NEW YORK, NY
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#1884 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from SELLAS Life Sciences Group, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$7.6MFY2021$1.0MFY2022$0FY2023n/aFY2024n/aFY2025
Net income
-$20.7MFY2021-$41.3MFY2022-$37.3MFY2023-$30.9MFY2024-$26.9MFY2025
SLS annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$7.6M$1.0M$0——
Net income-$20.7M-$41.3M-$37.3M-$30.9M-$26.9M
Diluted EPS-$1.34-$2.13-$1.34-$0.50-$0.25
Total assets$26.3M$20.9M$6.2M$19.4M$78.3M
Cash and equivalents$21.4M$17.1M$2.5M$13.9M$71.8M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

SLS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Apr 23, 2026DEF 14AFORM- DEF 14A· period Jun 16, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about SELLAS Life Sciences Group, Inc., by form type:

4 ×128-K ×10SCHEDULE 13G/A ×5SCHEDULE 13G ×310-Q ×2S-8 ×1ARS ×1DEFA14A ×1DEF 14A ×1S-3ASR ×110-K ×1EFFECT ×1CORRESP ×1
SLS recent filings
FiledFormWhat it isOriginal
Oct 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 31, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 27, 20268-KResults of operations; Other events· period Jul 24, 2026Document · Index
Jun 25, 20268-KDirector or officer change· period Jun 24, 2026Document · Index
Jun 18, 20268-KShareholder vote results· period Jun 16, 2026Document · Index
Jun 18, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 16, 2026Document · Index
Jun 16, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jun 2, 20268-KOther events· period Jun 2, 2026Document · Index
May 12, 20268-KResults of operations· period May 12, 2026Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
Apr 24, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Apr 23, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 23, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 23, 2026DEF 14AFORM- DEF 14A· period Jun 16, 2026Document · Index
Mar 27, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Mar 20, 2026S-3ASRSimplified registration statementDocument · Index
Mar 19, 20268-KResults of operations· period Mar 19, 2026Document · Index
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 11, 20268-KOther events· period Mar 11, 2026Document · Index
Feb 17, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 30, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 9, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 7, 2026Document · Index
Jan 8, 20268-KResults of operations; Other events· period Jan 7, 2026Document · Index
Dec 5, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 3, 2025Document · Index
Dec 5, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 3, 2025Document · Index
Dec 5, 20254Statement of changes in beneficial ownership (insider trade)· period Dec 3, 2025Document · Index
Nov 25, 2025EFFECTEFFECTDocument · Index
Nov 21, 2025CORRESPCORRESPDocument · Index
Nov 21, 20254Statement of changes in beneficial ownership (insider trade)· period Nov 19, 2025Document · Index
Nov 14, 2025SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Nov 12, 20258-KResults of operations· period Nov 12, 2025Document · Index

Insider filing activity

12 Form 4 filings appear in SELLAS Life Sciences Group, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New York

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001390478 and XBRL company facts. SELLAS Life Sciences Group, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.